Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis. (September 2016)

• Record Type: Journal Article
• Authors: Rios-Fernández, Raquel; Callejas-Rubio, Jose-Luis; García-Rodríguez, Sonia; Sancho, Jaime; Zubiaur, Mercedes; Ortego-Centeno, Norberto
• Is Part Of: American journal of therapeutics. Volume 23:Number 5(2016)
• Publication Date: 2016-09
• Subjects: hemophagocytic lymphohistiocytosis -- visceral leishmaniasis -- Leishmania -- tocilizumab -- interleukin 6; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; 615.58
• DOI: 10.1097/MJT.0000000000000035
• Languages: English
• ISSNs: 1075-2765

Abstract

Abstract : Leishmaniasis is important as a cause of hemophagocytic lymphohistiocytosis (HLH) and must be considered and excluded in patients with HLH because it can cause severe or even fatal complications. When HLH is present, there is a deficient downregulation of the immune response, leading to an uncontrolled inflammation. We report a case of visceral leishmaniasis-HLH where the therapy with tocilizumab, targeting interleukin 6, help to regulate the immune response for the infection of Leishmania .